Dexlanzoprazole API Manufacturers

Looking for Dexlanzoprazole API ?

Description:

Here you will find a list of producers, manufacturers and traders of Dexlanzoprazole. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Dexlanzoprazole 

Synonyms:

 

Cas Number:

 

DrugBank number:

 

Unique Ingredient Identifier:

Dexlanzoprazole is a type of Proton pump inhibitors

Proton pump inhibitors (PPIs) are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) commonly used for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related gastrointestinal conditions. PPIs work by inhibiting the gastric proton pump, which is responsible for the secretion of stomach acid.

The primary mechanism of PPIs involves blocking the final step in acid production, thereby reducing the amount of acid produced in the stomach. This inhibition occurs by binding irreversibly to the hydrogen-potassium ATPase enzyme system, also known as the proton pump, located on the parietal cells of the stomach lining. By reducing the acid levels, PPIs provide relief from the symptoms of acid reflux, such as heartburn and regurgitation, while promoting the healing of ulcers.

PPIs are available in various formulations, including delayed-release capsules, tablets, and oral suspensions. Some commonly prescribed PPIs include omeprazole, lansoprazole, pantoprazole, and esomeprazole. These medications are typically taken orally, with the dosage and duration of treatment determined by the severity of the condition and the individual patient's needs.

It is important to note that PPIs are intended for short-term use, generally ranging from four to eight weeks. Prolonged use of PPIs may lead to potential side effects, including an increased risk of gastrointestinal infections, vitamin and mineral deficiencies, and bone fractures.

In summary, proton pump inhibitors are a widely used subcategory of pharmaceutical APIs that effectively reduce stomach acid production. While they provide relief from acid-related conditions, careful consideration of their appropriate usage and potential side effects is necessary for optimal patient care.

Dexlanzoprazole (Proton pump inhibitors), classified under Gastrointestinal Agents

Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).

One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.

Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.

Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.

Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.

In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.